NASDAQ:NVCN - Neovasc Stock Price, Price Target & More

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings results on Wednesday, March, 28th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01. The medical equipment provider had revenue of $1.23 million for the quarter, compared to analysts' expectations of $1.18 million. Neovasc had a negative return on equity of 85.81% and a negative net margin of 1,687.90%. View Neovasc's Earnings History.

Neovasc is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Neovasc.

2 brokerages have issued 12-month price targets for Neovasc's stock. Their predictions range from $0.50 to $2.00. On average, they anticipate Neovasc's share price to reach $1.25 in the next twelve months. View Analyst Ratings for Neovasc.

Neovasc saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 74,020,430 shares, an increase of 55.3% from the April 13th total of 47,655,636 shares. Based on an average daily trading volume, of 87,826,510 shares, the days-to-cover ratio is presently 0.8 days. Currently, 83.5% of the shares of the stock are short sold.

Some companies that are related to Neovasc include IRadimed (IRMD), SeaSpine (SPNE), Apollo Endosurgery (APEN), Restoration Robotics (HAIR), Alphatec (ATEC), Sensus Healthcare (SRTS), INVO Bioscience (IVOB), Motus GI (MOTS), Invuity (IVTY), SANUWAVE (SNWV), Arch Therapeutics (ARTH), iCAD (ICAD), Spectral Medical (EDTXF), Repro-Med Systems (REPR) and CAS Medical Systems (CASM).

Media headlines about NVCN stock have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neovasc earned a media sentiment score of 0.18 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 45.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Neovasc's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (0.35%). View Institutional Ownership Trends for Neovasc.

NVCN stock was acquired by a variety of institutional investors in the last quarter, including Gagnon Securities LLC. View Insider Buying and Selling for Neovasc.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $0.03.

Neovasc has a market capitalization of $52.62 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]